The c-Met receptor tyrosine kinase is implicated in various
cancers due to its role in promoting malignant phenotypes and its association with poor outcomes.
VEGF/
VEGFR inhibition has become a standard treatment for some cancers, and recent findings indicate a synergistic effect between
RTKs in promoting cancer progression. Dual inhibition of
c-Met and VEGFRs is a promising therapeutic strategy, and several compounds targeting both have been clinically evaluated. However, clinical success has been limited due to issues with selectivity and toxicity from VEGFR inhibition, which affects tolerability and dosing.
To overcome these challenges,
TAS-115 was developed as a novel dual inhibitor of c-Met and VEGFRs. In vitro assays showed TAS-115 to be a potent ATP-competitive inhibitor of both targets, with an IC50 around 10 nM, surpassing known inhibitors like
crizotinib,
foretinib, and
sunitinib. TAS-115 effectively inhibited kinase phosphorylation and cell growth dependent on
HGF/c-Met or VEGF, with a significant selectivity advantage over other inhibitors. This selectivity was further validated across 40 cell lines, correlating IC50 values with HGF and c-Met mRNA expression.
In vivo studies demonstrated TAS-115's potent anti-tumor activity in both c-Met positive and negative xenografts, leading to complete tumor eradication and the disruption of c-Met and
VEGFR2 signaling pathways. The effective doses ranged from 4 to 30 mg/kg across 12 xenograft models. Notably, TAS-115 showed excellent tolerability with no animal deaths even at exposures 28 times higher than the ED50 values, contrasting favorably with other VEGFR inhibitors.
The study concludes that TAS-115 is a highly potent and selective c-Met and VEGFRs dual inhibitor with a safer profile, suggesting its potential as a therapeutic agent for human cancers. The research was presented at the 102nd Annual Meeting of the American Association for Cancer Research and published in Cancer Research.
How to Use Synapse Database to Search and Analyze Translational Medicine Data?
The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.

Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.

By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.

Click on the image below to go directly to the Translational Medicine search interface.
